<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
   <channel>
      <title>Allergy News</title>
      <link>http://allergy.immunodefence.com/</link>
      <description>Allergy News. Vaccine research and development.</description>
      <language>en</language>
      <copyright>Copyright 2008</copyright>
      <lastBuildDate>Tue, 24 Apr 2007 14:27:51 +0100</lastBuildDate>
      <generator>http://www.sixapart.com/movabletype/</generator>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs> 

            <item>
         <title>Stomach Bacterium May Thwart Asthma</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/pylori.jpg" border="0" alt="h.pylori" title="h.pylori" hspace="4" vspace="2" width="152" height="100" align="left" />April 23, 2007 -- A stomach bacterium that causes ulcers and is linked to stomach cancer may make asthma less likely.</p>     <p>That news appears in the <em>Archives of Internal Medicine</em>.</p>     <p>The bacterium is called <em>Helicobacter pylori</em> (H. pylori). It is associated with ulcers and increased risk of stomach cancer.</p>     <p>H. pylori is found worldwide, but it&#39;s more common in developing countries, note Yu Chen, PhD, MPH, and Martin Blaser, MD.</p>]]></description>
         <link>http://allergy.immunodefence.com/2007/04/stomach_bacterium_may_thwart_a.html</link>
         <guid>http://allergy.immunodefence.com/2007/04/stomach_bacterium_may_thwart_a.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">allergens</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">h.pylori</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">research</category>
        
         <pubDate>Tue, 24 Apr 2007 14:27:51 +0100</pubDate>
      </item>
            <item>
         <title>Inflammation, Asthma, and Tumor Necrosis Factor-alpha</title>
         <description><![CDATA[<p><em><img src="http://immunodefence.com/ii/tnf-alpha2.jpg" border="0" alt="tnf alpha diagram" title="tnf alpha diagram" hspace="4" vspace="2" align="right" />by Erwin W. Gelfand, MD</em> </p><p>Patients with severe and refractory asthma suffer from numerous complications, fatal disease, and utilize a large proportion of healthcare resources. Treatment options are certainly limited, and it is unclear what underlies their refractoriness to conventional therapy. Whether they are &quot;resistant&quot; to therapy with glucocorticoids or the pathophysiologic pathways involved in their disease are not sensitive to glucocorticoids is unclear at present. </p><p>Some phenotypic differences in patients with refractory asthma have emerged, such as a greater involvement of neutrophils, but the relevance of these data are not clear. Among the candidates identified as perhaps playing a role in refractory asthma is tumor necrosis factor-alpha (TNF-alpha), a pleiotropic inflammatory cytokine that is expressed in mast cells<sup>[1]</sup> and is present in higher concentrations in bronchoalveolar fluid from patients with asthma, particularly in bronchoalveolar lavage (BAL) fluid from patients with more severe asthma.<sup>[2]</sup></p>]]></description>
         <link>http://allergy.immunodefence.com/2007/04/inflammation_asthma_and_tumor.html</link>
         <guid>http://allergy.immunodefence.com/2007/04/inflammation_asthma_and_tumor.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">research</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">tnf alpha</category>
        
         <pubDate>Tue, 24 Apr 2007 14:18:47 +0100</pubDate>
      </item>
            <item>
         <title>Revolutionary new medical device offers hope for hayfever and allergy sufferers</title>
         <description><![CDATA[<img src="http://immunodefence.com/ii/medinose.jpg" border="0" alt="medinose" title="medinose" hspace="4" vspace="2" align="left" />Medinose heralds a breakthrough in the way hayfever and allergies are treated. Using photo therapy (light therapy) Medinose can practically eliminate allergic symptoms such as congestion, runny nose, watery eyes, and headaches within a couple of weeks of use.<br /><br /> Using photo therapy, Medinose inhibits the release of histamine, relieving or even completely eliminating allergic reactions and complaints in a natural way. The body is not burdened by drugs and Medinose has no side effects. Medinose consists of a small power pack (about the size of an IPOD) and two probes which are inserted into the nostrils.<br /><br /> Each treatment session with the Medinose takes just approx. 4.5 minutes 2-3 times a day. The Medinose can be used anywhere: at home, on the move or at work. With severe symptoms, treatment can be repeated several times without any side effects. As soon as the symptoms subside, the number of treatments can be reduced. The Medinose is, however, also suitable for prevention.  ]]></description>
         <link>http://allergy.immunodefence.com/2007/03/revolutionary_new_medical_devi.html</link>
         <guid>http://allergy.immunodefence.com/2007/03/revolutionary_new_medical_devi.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Allergic Rhinitis</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">allergic rhinitis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">medinose</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">preventing allergy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">treatment</category>
        
         <pubDate>Fri, 16 Mar 2007 20:02:27 +0100</pubDate>
      </item>
            <item>
         <title>Baking Soda Helps Kids During Severe Asthma Attack</title>
         <description><![CDATA[<img src="http://immunodefence.com/ii/asthma2.jpg" border="0" alt="asthma" title="asthma" hspace="4" vspace="2" width="100" height="100" align="right" /> <p>An intravenous infusion of a solution of sodium bicarbonate -- better known as  baking soda -- reduces respiratory distress and excessive acidity of body fluids  in children with a life-threatening asthma flare-up, according to a report from  the Netherlands.  </p><p>High blood acidity, or acidosis, causes the heart to contract less strongly,  reduces the effectiveness of beta-agonist bronchodilators used to treat asthma,  and may stimulate rapid, shallow breathing, Dr. Corinne M. P. Buysse and her  colleagues point out in the medical journal Chest.  </p><p>They explain that treatment with sodium bicarbonate has been shown to relieve  bronchial spasm and restore the response to bronchodilators. However, doctors  have avoided the use of intravenous sodium bicarbonate for fear of increasing  levels of carbon dioxide in the blood. </p>]]></description>
         <link>http://allergy.immunodefence.com/2007/03/baking_soda_helps_kids_during.html</link>
         <guid>http://allergy.immunodefence.com/2007/03/baking_soda_helps_kids_during.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">baking soda</category>
        
         <pubDate>Thu, 08 Mar 2007 20:50:31 +0100</pubDate>
      </item>
            <item>
         <title>Survey Shows Discomfort With Existing Nasal Sprays Causes Allergic Rhinitis Patients to Discontinue Treatment</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/allergy_schem.jpg" border="0" alt="allergy" title="allergy" hspace="4" vspace="2" width="100" height="109" align="left" />SAN DIEGO, Feb. 26 /PRNewswire/ -- A survey of more than 1,500 allergic rhinitis  sufferers who have used a prescription nasal spray to treat their symptoms  revealed that device and formulation-related attributes were the major causes of  discontinuing their treatment. The survey data (poster #896) were presented  today at the annual meeting of the American Academy of Allergy, Asthma &amp;  Immunology (AAAAI). </p><p>&quot;These results suggest compliance among nasal spray users could improve if new  technology overcomes the key barriers to continued use identified by these  patients,&quot; said Eli Meltzer, M.D., co-director of the Allergy &amp; Asthma  Medical Group and Research Center in San Diego, Calif., who led the survey.  &quot;This is important because nasal sprays, specifically intranasal  corticosteroids, are considered by medical experts as first-line therapy when  congestion is a major component of the patient&#39;s nasal allergy symptoms.&quot;&nbsp; </p>]]></description>
         <link>http://allergy.immunodefence.com/2007/03/survey_shows_discomfort_with_e.html</link>
         <guid>http://allergy.immunodefence.com/2007/03/survey_shows_discomfort_with_e.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Allergic Rhinitis</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">allergic rhinitis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">gsk</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">inhaled corticosteroid</category>
        
         <pubDate>Thu, 08 Mar 2007 19:31:18 +0100</pubDate>
      </item>
            <item>
         <title>Progress Against Peanut Allergies</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/peanuts.jpg" border="0" alt="peanuts allergy" title="peanuts allergy" hspace="4" vspace="2" width="100" height="121" align="right" />Small doses of peanut protein, given for months under medical supervision,  can desensitize children with peanut allergy, reducing the risk of a reaction if  they accidentally eat peanuts, according to a new study.</p> <p>In other new research, scientists say they have found a way to predict which  children are likely to outgrow their allergy to peanuts.</p> <p>Both studies were presented Saturday at the 2007 Annual Meeting of the  American Academy of Allergy, Asthma and Immunology in San Diego.</p>]]></description>
         <link>http://allergy.immunodefence.com/2007/03/progress_against_peanut_allerg.html</link>
         <guid>http://allergy.immunodefence.com/2007/03/progress_against_peanut_allerg.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Food Allergies</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">egg</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">immunotherapy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">peanuts</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">study</category>
        
         <pubDate>Wed, 07 Mar 2007 11:12:45 +0100</pubDate>
      </item>
            <item>
         <title>Gene find could be end of the asthma inhaler</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/inhaler_child.jpg" border="0" alt="inhaler" title="inhaler" hspace="4" vspace="2" width="153" height="100" align="left" />Scientists have identified a gene that could lead to a breakthrough in the treatment of asthma, with tablets replacing steroid inhalers.</p> <p>As a result of work carried out at Dundee University, researchers believe that drugs currently used to treat diabetes could be adapted to control acute asthma attacks.</p> <p>Until now asthma treatments have been dominated by steroid therapies which can often have serious side effects.</p>]]></description>
         <link>http://allergy.immunodefence.com/2007/03/gene_find_could_be_end_of_the.html</link>
         <guid>http://allergy.immunodefence.com/2007/03/gene_find_could_be_end_of_the.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">inhaled corticosteroid</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">inhalers</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">research</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">UK</category>
        
         <pubDate>Thu, 01 Mar 2007 13:10:59 +0100</pubDate>
      </item>
            <item>
         <title>What Is Known About Asthma In Africa?</title>
         <description><![CDATA[<img src="http://immunodefence.com/ii/asthma1.jpg" border="0" alt="asthma" title="asthma" hspace="4" vspace="2" width="100" height="100" align="right" />A study led by Adnan Custovic from the University of Manchester analyzing two surveys ten years apart (1993 and 2003) among 9-16 yr old schoolchildren attending urban and rural schools in Ghana showed that the prevalence of both exercise-induced bronchospasm and atopy had approximately doubled over the period. <br /><br /> A related essay puts this survey into context through a discussion of the epidemiology of asthma in Africa. <br /><br />Citation: Addo-Yobo EOD, Woodcock A, Allotey A, Baffoe-Bonnie B, Strachan D, et al. (2007) Exercise-induced bronchospasm and atopy in Ghana: Two surveys ten years apart. <em>PLoS Med</em> 4(2): e70. ]]></description>
         <link>http://allergy.immunodefence.com/2007/03/what_is_known_about_asthma_in.html</link>
         <guid>http://allergy.immunodefence.com/2007/03/what_is_known_about_asthma_in.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">africa</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">prevalence</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">risk scope</category>
        
         <pubDate>Thu, 01 Mar 2007 13:07:22 +0100</pubDate>
      </item>
            <item>
         <title>AAAAI: Oral Immunotherapy Dampens But May Not Cure Peanut Allergy</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/peanuts.jpg" border="0" alt="peanuts" title="peanuts" hspace="4" vspace="2" width="100" height="121" align="left" />SAN DIEGO -- An oral immunotherapy regimen can help take the sting out of severe peanut allergies, reported investigators here.</p><p>Five of seven children with severe peanut allergy were able, after two years of immunotherapy, to tolerate a dose of 7.8 grams of peanut flour, equivalent to eating more than 13 peanuts, reported Scott David Nash, M.D., of Duke in Durham, N.C., and colleagues.</p><p>Yet while oral immunotherapy can desensitize patients to peanuts, children who undergo it may not be in the clear, cautioned the authors in a featured poster session at the annual meeting of the American Academy of Allergy, Asthma &amp; Immunology here.</p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/aaaai_oral_immunotherapy_dampe.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/aaaai_oral_immunotherapy_dampe.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Food Allergies</category>
        
        
         <pubDate>Tue, 27 Feb 2007 13:36:56 +0100</pubDate>
      </item>
            <item>
         <title>Cows&apos; milk can protect against asthma</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/asthma2.jpg" border="0" alt="asthma" title="asthma" hspace="4" vspace="2" width="100" height="100" align="right" />Children who start drinking fresh milk from the farm early on are less likely to develop allergies when they are of school age, according to Swiss scientists.</p><p>But why more people are suffering allergies remains unclear, say researchers at Basel University, who have begun a study involving more than 14,000 children.</p>   						 <p>Cows&#39; milk as food for infants has a bad reputation. From a nutritional perspective it does not fulfil the dietary requirements of babies, and children who are fed only cows&#39; milk for too long often suffer an iron deficiency.</p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/cows_milk_can_protect_against.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/cows_milk_can_protect_against.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">childhood allergy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">milk</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">study</category>
        
         <pubDate>Tue, 27 Feb 2007 13:33:04 +0100</pubDate>
      </item>
            <item>
         <title>Finnish study links child asthma with structural dampness in buildings</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/asthma_kid.jpg" border="0" alt="childhood asthma" title="childhood asthma" hspace="4" vspace="2" width="149" height="100" align="left" /> A fresh study by the Environmental Health section of the National Public Health Institute shows a strong link between asthma in children and dampness in the building structures of the home.</p><p>According to an article in the upcoming edition of the European Respiratory Journal, at least one in ten, and possibly as many as one in five cases of asthma among children are linked with water damage in the building.</p><p>The onset of asthma is the result of the cumulative effect of many factors. Nevertheless, in the 1990s there was a rapid increase in cases of asthma in Finland, as well as an increase in damage caused by dampness in buildings. </p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/finnish_study_links_child_asth.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/finnish_study_links_child_asth.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">allergens</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">childhood allergy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">dampness</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">dust mite allergy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">study</category>
        
         <pubDate>Tue, 27 Feb 2007 13:26:49 +0100</pubDate>
      </item>
            <item>
         <title>Dynavax drops allergy drug trials</title>
         <description><![CDATA[<img src="http://immunodefence.com/ii/dynavax_logo.jpg" border="0" alt="dynavax" title="dynavax" hspace="4" vspace="2" width="167" height="43" align="right" />BERKELEY &mdash; Biopharmaceutical company Dynavax Technologies Corp. announced Friday it is discontinuing two clinical trials for its ragweed allergy treatment. <p>  The Berkeley-based company said it will explore developing a different path for trials for the treatment, called Tolamba.  </p><p> It announced Jan. 8 that trials for the drug were inconclusive, sending shares of the company&#39;s stock that day down 30 percent to just below $6. </p><p> &quot;It&#39;s not the death knell for the allergy program,&quot; said Shari Annes, a Dynavax spokeswoman. &quot;It was an inconclusive trial, not a failed drug.&quot; </p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/dynavax_drops_allergy_drug_tri.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/dynavax_drops_allergy_drug_tri.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Allergic Rhinitis</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">allergic rhinitis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">clinical trial</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">dynavax</category>
        
         <pubDate>Mon, 26 Feb 2007 15:56:39 +0100</pubDate>
      </item>
            <item>
         <title>Steroid-Free Astelin Nasal Spray Demonstrated Seasonal Allergy Symptom Improvement Within 15 Minutes in Clinical Study</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/astelin.jpg" border="0" alt="astelin" title="astelin" hspace="4" vspace="2" width="85" height="165" align="left" />The prescription antihistamine Astelin(R) (azelastine HCl) Nasal Spray(R) relieved the major symptoms of pollen allergy, including sneezing, runny nose and congestion, within 15 minutes of application compared to placebo and maintained efficacy at all time points for 8 hours in a randomized, single dose, double-blind, placebo- controlled study, MedPointe Pharmaceuticals announced today. </p><p>In addition, a group of patients treated with intranasal Nasonex(R) (mometasone furoate monohydrate) did not show symptom improvement compared to placebo during the eight hour study period. Data from the 450-patient study, conducted in a controlled environmental exposure unit (EEU), were presented at the 2007 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California.</p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/steroidfree_astelin_nasal_spra.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/steroidfree_astelin_nasal_spra.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Allergic Rhinitis</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">allergic rhinitis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">allergy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">astelin</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">clinical trial</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">ragweed</category>
        
         <pubDate>Mon, 26 Feb 2007 15:51:04 +0100</pubDate>
      </item>
            <item>
         <title>FDA Warns On Genentech&apos;s Asthma Drug Xolair</title>
         <description><![CDATA[<img src="http://immunodefence.com/ii/xolair.jpg" border="0" alt="xolair" title="xolair" hspace="4" vspace="2" align="right" />WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration warned Wednesday  a Genentech Inc. (DNA) asthma drug can cause a life-threatening allergic  reaction known as anaphylaxis.   <p>The agency said it&#39;s asked the company to put a black-box warning label on  the drug, which is sold under the brand name Xolair. A black box warning is the  FDA&#39;s strongest warning. </p> <p>Xolair was approved in 2003 to treat adults and adolescents with moderate to  severe persistent asthma related to allergies whose symptoms are inadequately  controlled with inhaled steroids. </p><p>A company spokesman couldn&#39;t immediately be reached. </p> <p>Genentech shares recently rose 8 cents to $87.02. </p><p><em>Copyright (c) 2007 Dow Jones &amp; Company, Inc.</em></p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/fda_warns_on_genentechs_asthma.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/fda_warns_on_genentechs_asthma.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Anaphylaxis</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">anaphylaxis</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">FDA</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">safety</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">xolair</category>
        
         <pubDate>Thu, 22 Feb 2007 22:10:07 +0100</pubDate>
      </item>
            <item>
         <title>Race May Play a Role in Children’s Asthma Care</title>
         <description><![CDATA[<p><img src="http://immunodefence.com/ii/asthma_kid.jpg" border="0" alt="asthma" title="asthma" hspace="4" vspace="2" width="149" height="100" align="left" />Newswise &mdash; Children in this country suffer from asthma more than any other chronic illness, and new research finds African-American children with the condition have a greater risk than others of experiencing severe symptoms that escalate into an emergency. </p><p>Previous research has shown that in comparison with white and Hispanic children, African-Americans have a higher rate of asthma, are hospitalized more and face more disability due to the condition. Because of this, &ldquo;we suspected they might also exhibit relatively more severe asthma symptoms at the time of hospitalization,&rdquo; said Yu Bai, a doctoral candidate at Pennsylvania State University.</p><p>Bai and his colleagues analyzed the records of 7,726 white, African-American and Hispanic children up to age 19 who were admitted to Pennsylvania hospitals in 2001 for asthma symptoms. The researchers then examined how the physician reported the severity of the children&rsquo;s condition and ranked them either as &ldquo;emergency&rdquo; or &ldquo;non-emergency&rdquo; admissions. </p>]]></description>
         <link>http://allergy.immunodefence.com/2007/02/race_may_play_a_role_in_childr.html</link>
         <guid>http://allergy.immunodefence.com/2007/02/race_may_play_a_role_in_childr.html</guid>
                  <category domain="http://www.sixapart.com/ns/types#category">Asthma</category>
        
                  <category domain="http://www.sixapart.com/ns/types#tag">asthma</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">childhood allergy</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">race</category>
                  <category domain="http://www.sixapart.com/ns/types#tag">research</category>
        
         <pubDate>Wed, 21 Feb 2007 14:47:28 +0100</pubDate>
      </item>
      
   </channel>
</rss>
